IDWeek 2026

IDWeek 2026
October 21-24, 2026
Washington D.C.

IDWeek 2026.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (17)

    Pharmacokinetic and Clinical Data Supporting the LEN Reloading Strategy for BIC/LEN Single-Tablet Regimen Dosing in the ARTISTRY Studies

    • Author(s): Arora P
    • bixlenvo
    • HIV / AIDS
    • Bixlenvo

    Metabolic and Safety Outcomes With BIC/LEN Single-Tablet Regimen in People With HIV and Comorbidities in ARTISTRY-2

    • Author(s): Ramgopal M
    • bixlenvo
    • HIV / AIDS
    • Bixlenvo

    Safety Analysis of BIC/LEN Single-Tablet Regimen in People With HIV Who Have Comorbidities of Dyslipidemia, Hypertension, and Diabetes Mellitus From Phase 3 of ARTISTRY-1

    • Author(s): Ramgopal M
    • bixlenvo
    • HIV / AIDS
    • Bixlenvo

    Efficacy and Safety Outcomes With BIC/LEN Single-Tablet Regimen in People With HIV and Renal Impairment in Phase 3 of ARTISTRY-1

    • Author(s): Hedgcock M
    • bixlenvo
    • HIV / AIDS
    • Bixlenvo

    Incidence of Resistance-Associated Mutations Among People With HIV Receiving B/F/TAF Versus DTG-Based Regimens

    • Author(s): Levintow S
    • biktarvy
    • HIV / AIDS

    Differences in Demographics and HIV Risk Exposures Among People Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Other Post-Exposure Prophylaxis Regimens in the United States, 2016-2025

    • Author(s): Mayer K
    • biktarvy
    • HIV / AIDS

    Baseline Characteristics and Substance Use Among People Who Inject Drugs With Evidence of Active Use in HPTN 103/PURPOSE 4: A Phase 2 Study of Twice-Yearly Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis

    • Author(s): Solomon S
    • yeztugo
    • truvada for prep
    • HIV / AIDS

    Resistance Analysis of Emergent Nsp12 Substitutions Observed in Immunocompromised COVID-19 Patients Treated With Remdesivir

    • Author(s): Rodriguez L
    • remdesivir
    • COVID-19

    Safety and Tolerability of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study

    • Author(s): Edwards A
    • gs-1179
    • Virology

    Efficacy and Virologic Analyses of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results from a Phase 1b Study

    • Author(s): Edwards A
    • gs-1179
    • Virology

    Changes in Pre-Exposure Prophylaxis Cost Sharing and HIV-1 Diagnoses Following United States Preventive Services Task Force and Affordable Care Act Coverage Milestones: An Interrupted Time Series Analysis

    • Author(s): Tao L
    • yeztugo
    • descovy for prep
    • truvada for prep
    • HIV / AIDS

    Efficacy and Safety of Once-Weekly Oral ISL/LEN Compared With B/F/TAF or Standard of Care in People With HIV-1 and Virologic Suppression: Week 48 Integrated Analysis From the Phase 3 ISLEND-1 and ISLEND-2 Trials

    • Author(s): Gupta S
    • isl/len
    • biktarvy
    • HIV / AIDS

    High Incidence of Sexually Transmitted Infections and Sexual Behaviors Associated with HIV Acquisition Among Cisgender Men and Gender-Diverse Individuals in PURPOSE 2

    • Author(s): Clement M
    • yeztugo
    • truvada for prep
    • HIV / AIDS

    Early Real-World Adoption Patterns of Long-Acting Lenacapavir for HIV PrEP in the United States (June 2025-March 2026)

    • Author(s): Tao L
    • yeztugo
    • HIV / AIDS

    Evaluating the National- and State-level Economic and Public Health Effect of Moderate Uptake of a Twice-Yearly Injectable PrEP Coupled With Minimal Overall PrEP Expansion in the General US Population and MSM

    • Author(s): Sullivan P
    • yeztugo
    • HIV / AIDS

    Low Incidence of Hepatitis B Infection Among People Receiving Lenacapavir or Tenofovir-Based HIV Pre-exposure Prophylaxis in PURPOSE 1 and PURPOSE 2

    • Author(s): Agwu A
    • yeztugo
    • descovy for prep
    • truvada for prep
    • HIV / AIDS

    Descriptive Evaluation of a Medical Affairs-Led Educational Resource to Support Healthcare Providers in the Implementation of Lenacapavir for HIV PrEP

    • Author(s): Fessler D
    • yeztugo
    • HIV / AIDS